HCW Biologics Inc.
HCWB
$1.18
-$0.27-18.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -93.16% | -96.34% | -98.93% | -99.55% | -70.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -93.16% | -96.34% | -98.93% | -99.55% | -70.18% |
| Cost of Revenue | -93.16% | -96.34% | -98.81% | -99.20% | -70.52% |
| Gross Profit | -93.16% | -96.37% | -99.28% | -99.84% | -68.73% |
| SG&A Expenses | 66.23% | -26.46% | -81.14% | -58.15% | -75.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.84% | -19.54% | -75.99% | -53.94% | -70.71% |
| Operating Income | -57.64% | 10.65% | 74.96% | 47.08% | 70.77% |
| Income Before Tax | 121.32% | -16.71% | 87.38% | 70.58% | 68.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 121.32% | -16.71% | 87.38% | 70.58% | 68.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 121.32% | -16.71% | 87.38% | 70.58% | 68.42% |
| EBIT | -57.64% | 10.65% | 74.96% | 47.08% | 70.77% |
| EBITDA | -94.92% | 12.31% | 76.86% | 51.08% | 76.51% |
| EPS Basic | 67.89% | 51.17% | 58.00% | 75.49% | 73.12% |
| Normalized Basic EPS | 51.44% | 61.53% | 86.03% | 53.18% | 73.12% |
| EPS Diluted | 67.89% | 51.17% | 58.00% | 75.49% | 73.12% |
| Normalized Diluted EPS | 51.44% | 61.53% | 86.03% | 53.18% | 73.12% |
| Average Basic Shares Outstanding | 220.01% | 139.01% | 88.25% | 20.02% | 17.51% |
| Average Diluted Shares Outstanding | 220.01% | 139.01% | 88.25% | 20.02% | 17.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |